Ikaros Degradation by Mezigdomide Reduces T-Cell Dysfunction and Improves the Efficacy of Antimyeloma T-Cell Therapies

Using bone marrow samples from multiple myeloma patients, scientists demonstrated a reduction in dysfunctional T cell populations expressing exhaustion markers such as TIGIT, upon treatment with Mezigdomide. They demonstrated the ability of Mezigdomide to enhance survival outcomes from anti-BCMA CAR-T therapy.